Ex vivo gene transfer in the years to come

AUTOR(ES)

Pap, Thomas

FONTE

BioMed Central

RESUMO

Synovial fibroblasts (SFs) have become a major target for ex vivo gene transfer in rheumatoid arthritis (RA), but efficient transduction of RA-SFs still is a major problem. The low proliferation rate and heterogeneity of RA-SFs, together with their lack of highly specific surface receptors, have hampered a more extensive application of this technique. Improving transduction protocols with conventional viral vectors, therefore, as well as developing novel strategies, such as alternative target cells, and novel delivery systems constitute a major challenge. Recent progress in this field will lead to the achievement of high transgene expression, and will facilitate the use of gene transfer in human trials.

Documentos Relacionados

• Hospital medical staffing: our hope for years to come.
• Adenoviral-mediated gene transfer to rabbit synovium in vivo.
• Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer.
• The value of necropsy in quality control of medical diagnosis: the gold standard for years to come
• Ex vivo nerve growth factor gene transfer to the basal forebrain in presymptomatic middle-aged rats prevents the development of cholinergic neuron atrophy and cognitive impairment during aging